businesspress24.com - Microbix Announces Annual and Special Meeting Voting Results
 

Microbix Announces Annual and Special Meeting Voting Results

ID: 1342365

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 03/06/15 -- Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, announces the results of the Annual and Special Meeting of Shareholders which was held on March 3, 2015, at which 46.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company''s Information Circular, which was filed on SEDAR on February 10, 2015. All of the nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:

In addition, shareholders approved: the appointment of the Company''s auditors; Collins Barrow Toronto LLP, amendments to the Company''s stock option plan; and amendments to warrants held by insiders.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the development of biological solutions, including products for vaccine and diagnostics markets worldwide. The company owns intellectual property for an approved biological drug, a vaccine technology and an animal reproduction technology. Established in 1988, Microbix is headquartered in Toronto.

Microbix'' pipeline of innovative technologies and products includes LumiSort® semen sexing technology for the livestock industry, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in influenza vaccine manufacture.

Please visit for recent Microbix Biosystems Inc. filings on its pipeline products and financial information.



Contacts:
Microbix Biosystems Inc.
Vaughn C. Embro-Pantalony
CEO
(905) 361-8910 (ext. 350)

Microbix Biosystems Inc.




Charles Wallace
CFO
(905) 361-8910 (ext. 255)


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Flamel Technologies to Report Fourth Quarter of Fiscal Year 2014 Results
Corbus Pharmaceuticals'' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab(TM)
Bereitgestellt von Benutzer: Marketwired
Datum: 06.03.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 1342365
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 160 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Microbix Announces Annual and Special Meeting Voting Results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Microbix Biosystems Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Microbix Biosystems Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 81


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.